Research progress of chidamide in treatment of tumor diseases

Histone deacetylase inhibitors (HDACi) are able to target intervention of the deacetylation of histone deacetylases(HDAC), desensitize the inhibition of gene transcription by hypoacetylation, re-express abnormally silenced genes, and promote cell differentiation or apoptosis, to achieve the treatment of neoplastic diseases. In recent years, many HDACi such as vorinostat, romidepsin and belinostat have appeared on the market and are used for the treatment of cutaneous T-cell lymphoma or peripheral T-cell lymphoma.Chidamide is entirely chemical synthesized, and it is a novel HDACi of benzamide, which aims at subtype 1, 2, 3 of classⅠHDAC and subtype 10 of class Ⅱb HDAC. Chidamide is researched and developmented independently by China, which is a broad-spectrum antitumor drug. This article summaries the studies of chidamide in treatment of tumor diseases. Key words: Histone deacetylase inhibitors; Chidamide; Neoplasms